Metrochem API Private Limited Metrochem API Private Limited

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"TVM Capital Life Science","sponsor":"TVM Capital Life Science","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"TVM Capital Life Science Announces Up To USD 24 Million Investment in Oncology Company, Recurv Pharma, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"TVM Capital Life Science","sponsor":"TVM Capital Life Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarit\u00c3\u00a9 FTQ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by TVM Capital Life Science

    Menu

    TVM Capital Life Science

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              TVM Capital Life Science

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ

              Details:

              The funding will be used to conduct a proof-of-concept study in a genetically selected sub-population of high-grade serous ovarian cancer. Esperas is developing the first oral Check 1 inhibitor, ESP-001 with the potential to treat certain types of cancers including HGSOC.

              Lead Product(s): ESP-001,Gemcitabine

              Therapeutic Area: Oncology Product Name: ESP-001

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: TVM Capital Life Science

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing February 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TVM Capital Life Science

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TVM Capital Life Science Announces Up To USD 24 Million Investment in Oncology Company, Recurv Pharma, Inc.

              Details:

              Recurv Pharma will use the funding in the development of a novel taxane therapy, RP-001, therapy to treat solid tumors. RP-001 is a new chemical entity (NCE) delivered in a nano-emulsion formulation that focuses the drug delivery to the tumor, sparing healthy organs.

              Lead Product(s): RP-001

              Therapeutic Area: Oncology Product Name: RP-001

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Recurv Pharma

              Deal Size: $24.0 million Upfront Cash: Undisclosed

              Deal Type: Financing February 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Veranova: A CDMO that manages complexity with confidence.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY